William Blair equity research analyst Matt Phipps was quoted in a MedCity News story focused on AbbVie’s $11 billion acquisition of eczema drugmaker Apogee.
“The timing of the acquisition allows AbbVie to accelerate Phase 3 development of Apogee’s lead drug and reduce future potential royalties owed to Blackstone,” Phipps wrote in a note to investors that was cited by the publication.